Lung Function, LCI, Bronchial Inflammation and Epigenetics of Patients With BO (FRABO-03)

December 9, 2015 updated by: Dr. med. Martin Rosewich, Johann Wolfgang Goethe University Hospital

Lungfunction, Lung Clearance Index, Bronchial Inflammation and Epigenetics of Patients With Bronchiolitis Obliterans

Bronchiolitis obliterans is a chronic disease in which a persistent inflammatory process leads to obliteration of the small airways. Pulmonary function tests (body plethysmography with DLCO, lung clearance index) are performed and the fraction of exhaled nitric oxide is measured. A blood test is following to determine the inflammatory status und collect miRNA. Induced Sputum will be obtained.

Study Overview

Status

Unknown

Intervention / Treatment

Detailed Description

The purpose of this study is to compare miRNA pattern, lung function values, bronchial inflammation and the Lung clearance index of Patients with Bronchiolitis obliterans aged between 6 up to 30 years of age with a matched control group.

The sputum samples will be processed and quantitatively analyzed to get a profile of the cytological composition.

Sputum and serum samples are analyzed by quantitative real-time polymerase chain reaction (qRT-PCR) and by cytometric bead assay (CBA). miRNA samples will be collected, processand compared with the miRNA database at http://www.mirbase.org/

Methods and Work Programme:

  • Measurement of nitric oxide in expired air (FeNO)
  • Lung function testing with spirometry and body plethysmography
  • Lung clearance index (LCI)
  • Bronchodilation
  • Blood test: blood count, CRP, RAST, serum inflammatory mediators, (genetic markers of the non-specific pulmonary defense system), miRNA analysis
  • Induced sputum for inflammatory mediators and microbiological investigations

Study Type

Observational

Enrollment (Anticipated)

20

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Hessen
      • Frankfurt am Main, Hessen, Germany, 60590
        • Recruiting
        • Children's Hospital, Goethe-University
        • Contact:
        • Contact:
        • Principal Investigator:
          • Martin Rosewich, MD
        • Sub-Investigator:
          • Stefan Zielen, MD, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

6 years to 35 years (Child, Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients with the assured diagnose of Bronchiolitis Obliterans and controls without this disease.

Description

Inclusion Criteria:

  • informed consent
  • age between 6 an 35 years
  • known bronchiolitis obliterans (Group Bronchiolitis)/ no Bronchiolitis Obliterans (Group matched controls)
  • ability to perform lung function tests and inhale correctly

Exclusion Criteria:

  • <6 years of age
  • >35 years of age
  • acute systemic or bronchial inflammation
  • other chronic diseases or infection (e.g. HIV, Tbc, malignoma)
  • pregnancy
  • alcohol, drug or illegal drug abuse
  • disability to register the range and consequences of the study
  • actual participation in another study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Subject Group
Patients suffering from Bronchiolitis Obliterans
Record lung function, Lung clearance index, inflammatory status
Control Group
Age and sex matched control group
Record lung function, Lung clearance index, inflammatory status

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
miRNA Status
Time Frame: single day observation
Blood sample to determine candidate miRNA for Bronchiolitis obliterans
single day observation

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Lung clearance index (LCI)
Time Frame: single day observation
Determine Lung clearance index with the Oxygen washout method
single day observation
FVC [%-pred.]
Time Frame: single day observation
Compare FVC [%-pred.] of BO Patients with a healthy control group
single day observation
FEV1 [%-pred.]
Time Frame: single day observation
Compare FEV1[%-pred.] of BO Patients with a healthy control group
single day observation
Tiffeneau Index
Time Frame: single day observation
Compare Tiffeneau-Index of BO Patients with a healthy control group
single day observation
sRtot [%-pred.]
Time Frame: single day observation
Compare sRtot[%-pred.] of BO Patients with a healthy control group
single day observation
RV/TLC [%-pred.]
Time Frame: single day observation
Compare RV/TLC[%-pred.] of BO Patients with a healthy control group
single day observation
DLCO [%-pred.]
Time Frame: single day observation
Compare difffusion capacity of the lung for CO [%-pred.] of BO Patients with a healthy control group
single day observation
IL-6 (pg/ml)
Time Frame: single day observation
Comparing IL-6 in Serum of patients with BO with a healthy control group
single day observation
IL-8 (pg/ml
Time Frame: single day observation
Comparing IL-8 in Serum of patients with BO with a healthy control group
single day observation
Il-17 (pg/ml)
Time Frame: single day observation
Comparing IL-17 in Serum of patients with BO with a healthy control group
single day observation
CrP (mg/dl)
Time Frame: single day observation
Comparing CrP in Serum of patients with BO with a healthy control group
single day observation
FeNO ppb
Time Frame: single day observation
Comparing FeNO in exhaled air of patients with BO with a healthy control group
single day observation
Sputum cell count
Time Frame: single day observation
Comparing sputum cell counts of patients with BO with a healthy control group
single day observation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Martin Rosewich, MD, Johann Wolfgang Goethe University Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2015

Primary Completion (Anticipated)

July 1, 2016

Study Registration Dates

First Submitted

December 9, 2015

First Submitted That Met QC Criteria

December 9, 2015

First Posted (Estimate)

December 11, 2015

Study Record Updates

Last Update Posted (Estimate)

December 11, 2015

Last Update Submitted That Met QC Criteria

December 9, 2015

Last Verified

December 1, 2015

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Bronchiolitis Obliterans

Clinical Trials on observation

3
Subscribe